• Eledon highlighted kidney transplant data showing tegoprubart delivered a statistically significant eGFR advantage versus tacrolimus by month 18, about 12 points.
• eGFR spread widened to about 10 points at month 21, about 19 points at month 24, supporting a potential durability benefit versus calcineurin inhibitors.
• BESTOW long-term extension showed no biopsy-proven acute rejection on tegoprubart after the first 6 months; tacrolimus recorded most rejections beyond 6 months.
• Phase 3 kidney transplant study planned with about 600 patients, primary endpoint non-inferiority on composite efficacy failure at 12 months versus tacrolimus.
• University of Chicago islet cell trial reported 12 of 12 patients achieved insulin independence, no severe hypoglycemic events post-transplant, HbA1c fell about 2.6%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.